Phase 2a Trial
The phase 2a Alzheimer’s disease study for LM11A-31 will be conducted in a network of sites based in Sweden, Germany, Austria and Czechoslovakia. Once appropriate approvals are in place the study is targeted to begin enrollment at some time during the summer of 2016. Since this six-month study will involve careful monthly testing with 8 or more visits, all of the participating subjects will be required to live near a study site. As is the case with most drug trials, approximately one-third of the trial participants will be treated with placebo, thus there is no guarantee that participants will receive the drug. Unfortunately, for this study there will be no participation options in the US. Once the trial is formally approved and set to begin, the specific sites and contact information will be listed on a number of websites including clinicaltrials.gov. At that time, study site directors can provide additional information regarding the logistics of potential participation. We expect the study to take approximately two years to complete. If the phase 2a study is successful, a phase 3 study will be conducted at many additional sites with a number likely to be in the US.